Prediction of fatal cardiovascular events in patients with newly diagnosed non-small cell lung cancer
https://doi.org/10.15829/15604071-2024-5877
EDN: XRNWDY
Abstract
Aim. To study risk factors for fatal cardiovascular events in patients with non-small cell lung cancer over two years of standard treatment.
Material and methods. This pilot retrospective non-randomized cohort study included 179 patients who were consecutively admitted to the chemotherapy department of City Clinical Hospital 1 from January to December 2020 with a confirmed diagnosis of non-small cell lung cancer based on the comprehensive examination and morphological verification according to the 2018 clinical guidelines on bronchial and lung cancer. Diagnosis and treatment of cardiovascular diseases were carried out according to national clinical guidelines. The follow-up period for non-small cell lung cancer and cardiovascular disease was 2 years. Logistic regression models were considered to assess the risk of cardiovascular death. The model accuracy was assessed by a cross-validation.
Results. The best model in terms of the sensitivity and specificity sum according to a cross-validation was the model with the following explanatory variables: sex, cancer stage, platinum-based chemotherapy, etoposide, immunotherapy, surgical treatment. This model showed a sensitivity of 70,1% and a specificity of 82,1%.
Conclusion. This approach is easy to implement and may optimize treatment for patients with non-small cell lung cancer.
Supporting agencies: FWNF-2024-0001
About the Authors
A. A. Filippov
City Clinical Hospital № 1
Russian Federation
Competing Interests:
Russian Federation
head of the polychemotherapy department
Novosibirsk
Competing Interests:
none
N. G. Lozhkina
City Clinical Hospital № 1; Federal Research Center for Fundamental and Translational Medicine; Novosibirsk National Research State University
Russian Federation
Competing Interests:
Russian Federation
Professor, Head of Clinical and Experimental Cardiology Group, Federal State Budgetary Scientific Institution "Federal Research Center for Fundamental and Translational Medicine" (FRC FTM), Professor of the Immunology Department, Federal State Autonomous Educational Institution of Higher Professional Education "Novosibirsk National Research State University", Cardiologist, Supervisor of Department for treatment of patients with acute coronary syndrome of RCVC №1 of Municipal Clinical Hospital №1
Novosibirsk
Competing Interests:
none
E. I. Shefer
Sobolev Institute of Mathematics
Russian Federation
Competing Interests:
Russian Federation
senior researcher,Institute of Mathematics named after S.L. Sobolev
Novosibirsk
Competing Interests:
none
P. S. Ruzankin
Sobolev Institute of Mathematics
Russian Federation
Competing Interests:
Russian Federation
chief scientist, Institute of Mathematics named after S.L. Sobolev
Novosibirsk
Competing Interests:
none
M. I. Voevoda
Federal Research Center for Fundamental and Translational Medicine
Russian Federation
Competing Interests:
Russian Federation
academician of the Russian Academy of Sciences, Doctor of Medical Sciences, Professor, Director of FRC FTM
Novosibirsk
Competing Interests:
none
References
1. Zaborowska-Szmit M, Krzakowski M, Kowalski DM, Szmit S. Cardiovascular Complications of Systemic Therapy in NonSmallCell Lung Cancer. J Clin Med. 2020;9(5):1268. doi:10.3390/jcm9051268.
2. Ananthan K, Lyon AR. The Role of Biomarkers in Cardio-Oncology. J Cardiovasc Transl Res. 2020;13(3):43150. doi:10.1007/s12265020100423.
3. Mareev VYu, Fomin IV, Ageev FT, et al. Russian Heart Failure Society, Russian Society of Cardiology. Russian Scientific Medical Society of Internal Medicine Guidelines for Heart failure: chronic (CHF) and acute decompensated (ADHF). Diagnosis, prevention and treatment. Kardiologiia. 2018;58(6S):8158. (In Russ.) doi:10.18087/cardio.2475.
4. Kobalava ZhD, Konradi AO, Nedogoda SV, et al. Arterial hypertension in adults. Cli nical guidelines 2020. Russian Journal of Cardiology. 2020;25(3):3786. (In Russ.) doi:10.15829/15604071202033786.
5. Russian Society of Cardiology (RSC) 2020 Clinical practice guidelines for Stable coronary artery disease. Russian Journal of Cardiology. 2020;25(11):4076. (In Russ.) doi:10.15829/29/1560407120204076.
6. Arakelyan MG, Bockeria LA, Vasilieva EYu, et al. 2020 Clinical guidelines for Atrial fibril lation and atrial flutter. Russian Journal of Cardiology. 2021;26(7):4594. (In Russ.) doi:10.15829/1560407120214594.
7. Jain V, Al Rifai M, Brinzevich D, et al. Association of premature atherosclerotic cardiovascular disease with higher risk of cancer: a behavioral risk factor surveillance system study. Eur J of Prev. Cardiol. 2022;29(3):493501. doi:10.1093/eurjpc/zwab084.
8. Calvillo-Argüelles O, Jaiswal S, Shlush LI, et al. Connections between clonal hematopoiesis, cardiovascular disease, and cancer: a review. JAMA Cardiol. 2019;4(4):3807. doi:10.1001/jamacardio.2019.0302.
9. Asada S, Kitamura T. Clonal hematopoiesis and associated diseases: a review of recent findings. Cancer Sci. 2021;112(10):396271.
10. Al-Hawwas M, Tsitlakidou D, Gupta N, et al. Acute coronary syndrome management in cancer patients. Curr. Oncol. 2018;20(10):78. doi:10.1007/s1191201807248.
11. Behinaein P, Treffalls J, Hutchings H, Okereke IC. The Role of Sublobar Resection for the Surgical Treatment of Non-Small Cell Lung Cancer. Current Oncology. 2023;30(7):701930. doi:10.3390/curroncol30070509.
12. Altena R, Hubbert L, Kiani NA, et al. Evidence-based prediction and prevention of cardiovascular morbidity in adults treated for cancer. Cardio-Oncology. 2021;7(1):20. doi:10.1186/s4095902100105y.
13. Lyon LR, López-Fernández T, Couch LS, et al. ESC Scientific Document Group, 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (ICOS): Developed by the task force on cardio-oncology of the European Society of Cardiology (ESC). European Heart Journal. 2022;43(41):4229361. doi:10.1093/eurheartj/ehac244.
Supplementary files
- Non-small cell lung cancer and cardiovascular diseases occur together in most patients, increasing the cumulative risk of fatal cardiovascular outcome.
- The author's risk assessment model of a fatal cardiovascular outcome is proposed, constructed using the regression analysis of clinical, functional, biochemical, and pathomorphological parameters.
- The risk assessment model of a fatal cardiovascular outcome is easy to use and allows for personalized management of patients with non-small cell lung cancer.
Review
For citations:
Filippov A.A., Lozhkina N.G., Shefer E.I., Ruzankin P.S., Voevoda M.I. Prediction of fatal cardiovascular events in patients with newly diagnosed non-small cell lung cancer. Russian Journal of Cardiology. 2024;29(7):5877. (In Russ.) https://doi.org/10.15829/15604071-2024-5877. EDN: XRNWDY
Views:
258
Email this article 